KAYEXALATE is a cation-exchange resin prepared in the sodium phase, with an in vivo exchange capacity of approximately 1 mmol (in vitro approximately 3.1 mmol) of potassium per gram. Polystyrene sulfonate (resonium) 0.3-1 g/kg 6 hourly (max 15-30 g) PR or oral (with lactulose) Note: NOT to be used if ileus, recent abdominal surgery, perforation, hypernatraemia Onset of Action: 1 hour PR, 4-6 hours oral Duration: variable 36, No. sodium polystyrene sulfonate. Persons with chronic kidney disease (CKD), diabetes, or heart failure treated with renin-angiotensin-aldosterone system (RAAS)-blocking agents are at an increased risk for hyperkalemia.1-4 Although mild to moderate hyperkalemia (serum potassium, 5.0-6.0 mEq/L) is often asymptomatic, severe hyperkalemia (serum potassium > 6.0 mEq/L) can cause cardiac arrhythmias and death.1 Hyperkalemia … Hyperkalemia is a potentially life-threatening metabolic problem caused by inability of the kidneys to excrete potassium, impairment of the mechanisms that … IV, intravenously. Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 120 mL bottle, NDC 00054-0379-50; Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 500 mL bottle, NDC 00054-0379-63 - discontinued Calcium Resonium contains calcium polystyrene sulfonate which contains calcium atoms. Calcium Resonium does not enter the bloodstream from the intestine. Storage And Handling. Kayexalate (Sodium polystyerene sulfonate) is a cation-exchange resin that was approved in 1958 as a treatment for hyperkalemia by helping to exchange sodium for potassium in the colon and thus excreting potassium from the body. This drug has been a standard part of treatment of hyperkalemia for decades. KAYEXALATE is available as a cream to light brown, finely ground powder in jars of 1 pound (453.6 g), NDC 59212-075-01. KAYEXALATE is a cream to light brown, finely ground powder and is available in 453.6 g jars. Resonium-A (Kayexalate)(Na polystyrene sulfonate): Learn about Resonium-A (Kayexalate)'s Dosage, Side Effects and indications KAYEXALATE is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula: The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an . US Pharm. Crit Care Med 2008 Vol. Colonic necrosis and perforation following oral sodium polystyrene sulfonate (Resonium A/Kayexalate) in a burn patient. Calcium Resonium is a type of medicine used to help remove excessive amounts of potassium from the blood. 12 3247. agent is the gluconate salt, since it is less This calcium is swapped for potassium in the body, particularly in the large intestine. 2017;42(2):HS15-HS18.. ABSTRACT: Hyperkalemia (elevated serum potassium) can become a life-threatening electrolyte abnormality due to medication use, kidney dysfunction, or alternative sources of electrolyte imbalance.Up until recently, FDA-approved therapies for the management of hyperkalemia (i.e., sodium polystyrene sulfonate) had remained unchanged for over 50 years. KAYEXALATE can be administered either orally or as an enema. Burns 2002;28: 189-190. Cheng ES, Stringer KM, Pegg SP. (Kayexalate, Kionex) 15–30 g in 15–30 mL (70% sorbitol orally) 2 hrs 4–6 hrs Variable efficacy intestinal necrosis Hemodialysis Immediate 3 hrs Arrhythmias (?) Resonium. Background: Hyperkalemia is one of the most dreadful complications of chronic kidney disease (CKD). The sodium content is approximately 4.1 mmol (100 mg) per gram of the drug. Products Affected - Description. Mild effect, multiple doses necessary, may be used as long term agent. Medical management includes use of cation exchange resins to reduce the amount of excessive potassium from the body. Sodium polystyrene sulphonate (SPS) and calcium polystyrene sulphonate (CPS) are currently used for hyperklemia of CKD all over the world.